SCHEMBL20914226

SCHEMBL20914226

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nnc(C2CCNCC2)o1

nearest known ligand 0.47

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ PLAT P00750 18/20 0.47
▸ HTR4 Q13639 1/20 0.40
▸ OPRM1 P35372 1/20 0.37
▸ GPR4 P46093 1/20 0.37
▸ HTR3A P46098 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ TMEM97 Q5BJF2 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914007 0.93 PLAT (0.43) PLAT
SCHEMBL20914105 0.92 PLAT (0.42) PLAT
SCHEMBL20914147 0.91 PLAT (0.38) PLATHTR4KCNH2
SCHEMBL20913972 0.91 PLAT (0.42) PLAT
SCHEMBL20914101 0.88 MAPT (0.40) PLAT
SCHEMBL20931237 0.88 PLAT (0.36) PLAT
SCHEMBL20913954 0.88 PLAT (0.36) PLAT
SCHEMBL20914256 0.88 HDAC3 (0.43) —
SCHEMBL20914301 0.87 PLAT (0.38) PLAT
SCHEMBL20914350 0.87 PLAT (0.38) PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 PLAT 1323/4885HTR4 1634/4885OPRM1 4729/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 PLAT 1323/4885HTR4 1634/4885OPRM1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback